Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa…

By N. Thatcher, A. Chang, P. Parikh, J. Rodrigues Pereira, T. Ciuleanu, J. von Pawel, S. Thongprasert, E. Tan, K. Pemberton, V. Archer and 1 more. The Lancet, 2005

2,150 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/30f3171754cb7dc0a7ebd250476ef97e5d706df1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. J. Engelman
2. P. Jänne
3. William Pao
4. Jie Yang
5. Adi F. Gazdar
6. K. Imai
7. A. Takaoka
8. S. Rosenberg

In Pulmonary and Respiratory Medicine

1. B. Hughes
2. B. Chan
3. J. Engelman
4. William Pao
5. L. Sequist
6. P. Jänne
7. Marc Ladanyi
8. Adi F. Gazdar

Citations in the corpus

• Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. (2015, background): “Two early phase III trials investigated EGFR TKIs versus placebo in second- or third-line in unselected patients, prior to knowledge of predictive biomarkers (Table 1) (56,57).”
• Comparing antibody and small-molecule therapies for cancer (2006, background): “On the other hand, diarrhoea is not common in patients treated with mAbs but is in patients treated with small-molecule inhibitor”
• Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. (2013, background): “Gefitinib and erlotinib were initially considered salvage therapies, with low response rates but marginal improvement in survival compared with placebo in unselected patients.(19,20) Once the qualitative difference in response to EGFR TKIs among EGFR-mutant patients was appreciated, randomized studi”
• Organoid cultures derived from patients with advanced prostate cancer (2014, neutral): “As exemplified by gefitinib in non-small-cell lung cancer, many drugs can lead to extraordinary responses in small subsets of patients, which, when left unidentified, result in negative clinical trials (Thatcher et al., 2005).”
• Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses (2010, background): “If a subgroup effect is real, it is likely to manifest itself across all closely related outcomes. For example, in a randomised trial of 1692 patients with refractory non-small-cell lung cancer, Thatcher et al”
• Lung cancer in never smokers — a different disease (2007, background): “These observations led to the development and widespread clinical testing of small-molecule tyrosine kinase inhibitors (TKIs) including erlotinib (Tarceva) and gefitinib (Iressa”